The Bulletin
Times Advertising


.

UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's disease, in its Phase 1 study

  • Written by PR Newswire

SHANGHAI, May 23, 2025 /PRNewswire/ -- Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson's disease cell drug UX-DA001 in China in March 2025. The Phase I clinical trial aims to evaluate the safety,...

The Bulletin Magazine

Who Should Consider Mole Mapping in Melbourne?

Why Buy Carbohydrate Supplements Are Essential For Weight Gain And Bodybuilding Performance

Engineered Timber Floors Melbourne: Creating Timeless And Durable Interiors

Year 12 Tutoring Helping Students Navigate Their Most Important Academic Year

Simple Home Upgrades That Improve Security, Comfort and Everyday Living

What is a Design and Build Contract? A Complete Guide

How Melbourne Homeowners Keep Their Homes Clean Year-Round (Without Spending Their Weekends Doing It)

Why Choosing The Right GP Bundoora Is Key To Long-Term Health Management

Why BMW Used Cars Are A Smart Choice For Modern Drivers

SMSF Loan Experts Guiding Smarter Property Investment Through Super

Why Professional Cleaning Services Are Essential For Commercial Workspaces

From Purchase to Protection: What Happens After You Buy a Home

hacklink hack forum hacklink film izle hacklink betturkeydepo 5ksahabetroyalbet girişslogan bahis resmiRocket Playcasibomiptv satın aliptv satın alcasibomtaraftarium24casibomjojobetholiganbet 1236holiganbetmarsbahis